Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Indian scientists said Tuesday they had made a breakthrough that could lead to diabetics needing to inject themselves only once a month or less, rather than every day.
Researchers at the National Institute of Immunology in New Delhi said they had successfully concluded a two-year trial on mice, rats and rabbits of a drug which slowly releases insulin into the body over weeks or even months.
Reporting in the US journal Proceedings of the National Academy of Sciences (PNAS), they said a single dose of the drug - SIA-II - was able to maintain a minimum level of insulin in a rat for more than 120 days.
"I think this is a very exciting development," Anoop Misra, director of the diabetes department at Fortis Hospitals in New Delhi, and chairman of the Diabetes Foundation (India), told AFP.
Misra said once-a-week injections for diabetes were making good progress in trials but that monthly injections were pioneering territory.
"This longer control of diabetes with a single reservoir of insulin is entirely new, though one must keep in mind this has been done just in animal models," he said of the prototype drug.
"It is still in the early stages of development."
Avadhesha Surolia, director of the National Institute of Immunology and one of the paper's authors, told the Mint newspaper that the technology had been licensed to Life Science Pharmaceuticals in Connecticut.
He described the agreement as "one of the biggest licensing deals from any academic institution in India."
More than 220 million people worldwide suffer from diabetes, which kills more than one million people each year, according to the World Health Organization (WHO).
The illness is affecting a growing number of people across Asia because of a combination of modern diets, increasingly urban living and genetics.
Some diabetics have to inject insulin every few hours and must carefully watch their diet and blood sugar levels because their bodies are unable to break down glucose in the blood.
bgs/ri/apj/bsk
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments